Chronic granulomatous disease: Why an inflammatory disease?

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 11, 2014, Pages 924-928

  Roxo Junior, P ^a   Simao H M L ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SANTA CRUZ DO SUL   (Brazil)

Author keywords

Chronic granulomatous disease; Granulomas; Infection; Inflammation; NADPH oxidase

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL; CALGRANULIN A; CALGRANULIN B; CYCLOSPORIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2, 3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 17; LEUKOTRIENE; PROSTAGLANDIN; PROTEIN S 100; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; STEROID; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; AUTACOID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

APOPTOSIS; BONE MARROW CELL; CHRONIC GRANULOMATOUS DISEASE; COLITIS; CROHN DISEASE; DIGESTIVE SYSTEM INFLAMMATION; EOSINOPHIL; FIBROSIS; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION; GRANULOMA; HUMAN; INNATE IMMUNITY; LUNG EDEMA; MACROPHAGE; NEUTROPHIL; NONHUMAN; PROTEIN DEFICIENCY; REPERFUSION INJURY; REVIEW; SYSTEMATIC REVIEW; TUBERCULOSIS; X CHROMOSOMAL INHERITANCE; DEFICIENCY; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

GRANULOMATOUS DISEASE, CHRONIC; HUMANS; INFLAMMATION MEDIATORS; NADPH OXIDASE; NEUTROPHILS; REACTIVE OXYGEN SPECIES;

EID: 84923385972     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20143735     Document Type: Review

References (48)

1. Roos D, Kuhns DB, Maddalena A, Bustamante J, Kannengiesser C, de Boer M, et al. Hematologically important mutations: the autosomal recessive forms of chronic granu-lomatous disease (second update). Blood Cells Mol Dis 2010; 44: 291-299, doi: 10.1016/j.bcmd.2010.01.009.
2. Roos D, Kuhns DB, Maddalena A, Roesler J, Lopez JA, Ariga T, et al. Hematologically important mutations: X-linked chronic granulomatous disease (third update). Blood Cells Mol Dis 2010; 45: 246-265, doi: 10.1016/j.bcmd.2010.07.012.
3. Rieber N, Hector A, Kuijpers T, Roos D, Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol 2012; 2012: 252-460, doi: 10.1155/2012/252460.
4. Jakobsen MA, Katzenstein TL, Valerius NH, Roos D, Fisker N, Mogensen TH, et al. Genetical analysis of all Danish patients diagnosed with chronic granulomatous disease. Scand J Immunol 2012; 76: 505-511, doi: 10.1111/j.1365-3083.2012.02771.x.
5. Heyworth PG, Curnutte JT, Rae J, Noack D, Roos D, van Koppen E, et al. Hematologically important mutations: X-linked chronic granulomatous disease (second update). Blood Cells Mol Dis 2001; 27: 16-26, doi: 10.1006/bcmd.2000.0347.
6. Ahlin A, De Boer M, Roos D, Leusen J, Smith CI, Sundin U, et al. Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden. Acta Paediatr 1995; 84: 1386-1394, doi: 10.1111/j.1651-2227.1995.tb13575.x.
7. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol 2010; 125: S3-S23, doi: 10.1016/j.jaci.2009.12.980.
8. Desjardins A, Coignard-Biehler H, Mahlaoui N, Frange P, Bougnoux ME, Blanche S, et al. Chronic granulomatous disease: pathogenesis and therapy of associated fungal infections. Med Sci 2012; 28: 963-969.
9. Alsultan A, Williams MS, Lubner S, Goldman FD. Chronic granulomatous disease presenting with disseminated intra-cranial aspergillosis. Pediatr Blood Cancer 2006; 47: 107-110, doi: 10.1002/pbc.20426.
10. Seger RA. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med 2010; 68: 334-340.
11. Ben-Ari J, Wolach O, Gavrieli R, Wolach B. Infections associated with chronic granulomatous disease: linking genetics to phenotypic expression. Expert Rev Anti Infect Ther 2012; 10: 881-894, doi: 10.1586/eri.12.77.
12. de Oliveira-Junior EB, Prando C, Lopez JA, Arango JC, Buzolin M, Rehder J, et al. High-performance liquid chromatography under partially denaturing conditions (dHPLC) is a fast and cost-effective method for screening molecular defects: four novel mutations found in X-linked chronic granulomatous disease. Scand J Immunol 2012; 76: 158-166, doi: 10.1111/j.1365-3083.2012.02714.x.
13. Roxo P Jr, de Menezes UP, Condino-Neto A, Ferriani VP, Takayanagui OM. Unusual presentation of brain aspergillo-sis in chronic granulomatous disease. Pediatr Neurol 2010; 43: 442-444, doi: 10.1016/j.pediatrneurol.2010.06.020.
14. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine 2000; 79: 155-169, doi: 10.1097/00005792-200005000-00003.
15. Liu W, Yan M, Sugui JA, Li H, Xu C, Joo J, et al. Olfm4 deletion enhances defense against Staphylococcus aureus in chronic granulomatous disease. J Clin Invest 2013; 123: 3751-3755, doi: 10.1172/JCI68453.
16. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4: 181-189, doi: 10.1038/nri1312.
17. Babior BM. The NADPH oxidase of endothelial cells. IUBMB Life 2000; 50: 267-269, doi: 10.1080/15216540051080976.
18. Babior BM. NADPH oxidase. Curr Opin Immunol 2004; 16: 42-47, doi: 10.1016/j.coi.2003.12.001.
19. El-Benna J, Dang PM, Gougerot-Pocidalo MA. Priming of the neutrophil NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to the plasma membrane. Semin Immunopathol 2008; 30: 279-289, doi: 10.1007/s00281-008-0118-3.
20. Chessa TA, Anderson KE, Hu Y, Xu Q, Rausch O, Stephens LR, et al. Phosphorylation of threonine 154 in p40phox is an important physiological signal for activation of the neutrophil NADPH oxidase. Blood 2010; 116: 6027-6036, doi: 10.1182/blood-2010-08-300889.
21. Lambeth JD. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007; 43: 332-347, doi: 10.1016/j.freeradbiomed.2007.03.027.
22. Schappi MG, Jaquet V, Belli DC, Krause KH. Hyperinflammation in chronic granulomatous disease and anti-inflammatory role of the phagocyte NADPH oxidase. Semin Immunopathol 2008; 30: 255-271, doi: 10.1007/s00281-008-0119-2.
23. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 8: 837-848, doi: 10.1038/nri2423.
24. Weissmann N, Sydykov A, Kalwa H, Storch U, Fuchs B, Schnitzler M, et al. Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. Nat Commun 2012; 3: 649, doi: 10.1038/ncomms1660.
25. Gandhirajan RK, Meng S, Chandramoorthy HC, Mallilankaraman K, Mancarella S, Gao H, et al. Blockade of NOX2 and STIM1 signaling limits lipopolysaccharide-induced vascular inflammation. J Clin Invest 2013; 123: 887-902.
26. Whitmore LC, Hilkin BM, Goss KL, Wahle EM, Colaizy TT, Boggiatto PM, et al. NOX2 protects against prolonged inflammation, lung injury, and mortality following systemic insults. J Innate Immun 2013; 5: 565-580, doi: 10.1159/000347212.
27. Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125: S182-S194, doi: 10.1016/j.jaci.2009.07.053.
28. von Rosenvinge EC, O’Donnell TG, Holland SM, Heller T. Chronic granulomatous disease. Inflamm Bowel Dis 2010; 16: 9, doi: 10.1002/ibd.20912.
29. Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O’Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics 2004; 114: 462-468, doi: 10.1542/peds.114.2.462.
30. Dinauer MC. Chronic granulomatous disease and other disorders of phagocyte function. Hematology Am Soc Hematol Educ Program 2005; 89-95, doi: 10.1182/asheducation-2005.1.89.
31. Schappi MG, Klein NJ, Lindley KJ, Rampling D, Smith VV, Goldblatt D, et al. The nature of colitis in chronic granulomatous disease. J Pediatr Gastroenterol Nutr 2003; 36: 623-631, doi: 10.1097/00005176-200305000-00006.
32. LeVine S, Smith VV, Malone M, Sebire NJ. Histopathological features of chronic granulomatous disease (CGD) in childhood. Histopathology 2005; 47: 508-516, doi: 10.1111/j.1365-2559.2005.02258.x.
33. 2+ influx in human neutrophil granulo-cytes. Alterations in chronic granulomatous disease. J Biol Chem 1997; 272: 26471-26478, doi: 10.1074/jbc.272.42.26471.
34. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313, doi: 10.1152/physrev.00044.2005.
35. Deng J, Wang X, Qian F, Vogel S, Xiao L, Ranjan R, et al. Protective role of reactive oxygen species in endotoxin-induced lung inflammation through modulation of IL-10 expression. J Immunol 2012; 188: 5734-5740, doi: 10.4049/jimmunol.1101323.
36. Berthier S, Nguyen MV, Baillet A, Hograindleur MA, Paclet MH, Polack B, et al. Molecular interface of S100A8 with cytochrome b558 and NADPH oxidase activation. PLoS One 2012; 7: e40277, doi: 10.1371/journal.pone.0040277.
37. Brown JR, Goldblatt D, Buddle J, Morton L, Thrasher AJ. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol 2003; 73: 591-599, doi: 10.1189/jlb.1202599.
38. Harrison CA, Raftery MJ, Walsh J, Alewood P, Iismaa SE, Thliveris S, et al. Oxidation regulates the inflammatory properties of the murine S100 protein S100A8. J Biol Chem 1999; 274: 8561-8569, doi: 10.1074/jbc.274.13.8561.
39. Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol 2006; 27: 244-250, doi: 10.1016/j.it.2006.03.005.
40. Henson PM. Dampening inflammation. Nat Immunol 2005; 6: 1179-1181, doi: 10.1038/ni1205-1179.
41. Sanford AN, Suriano AR, Herche D, Dietzmann K, Sullivan KE. Abnormal apoptosis in chronic granulomatous disease and autoantibody production characteristic of lupus. Rheumatology 2006; 45: 178-181, doi: 10.1093/rheumatology/kei135.
42. Fernandez-Boyanapalli R, McPhillips KA, Frasch SC, Janssen WJ, Dinauer MC, Riches DW, et al. Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-gamma in a nitric oxide-dependent manner. J Immunol 2010; 185: 4030-4041, doi: 10.4049/jimmunol.1001778.
43. Hartl D, Lehmann N, Hoffmann F, Jansson A, Hector A, Notheis G, et al. Dysregulation of innate immune receptors on neutrophils in chronic granulomatous disease. J Allergy Clin Immunol 2008; 121: 375-382, doi: 10.1016/j.jaci.2007.10.037.
44. Schappi M, Deffert C, Fiette L, Gavazzi G, Herrmann F, Belli D, et al. Branched fungal beta-glucan causes hyperinflam-mation and necrosis in phagocyte NADPH oxidase-deficient mice. J Pathol 2008; 214: 434-444, doi: 10.1002/path.2298.
45. Foster CB, Lehrnbecher T, Mol F, Steinberg SM, Venzon DJ, Walsh TJ, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 1998; 102: 2146-2155, doi: 10.1172/JCI5084.
46. Holmes B, Page AR, Good RA. Studies of the metabolic activity of leukocytes from patients with a genetic abnormality of phagocytic function. J Clin Invest 1967; 46: 1422-1432, doi: 10.1172/JCI105634.
47. Holmes B, Quie PG, Windhorst DB, Good RA. Fatal granulomatous disease of childhood. An inborn abnormality of phagocytic function. Lancet 1966; 1: 1225-1228, doi: 10.1016/S0140-6736(66)90238-8.
48. Segal BH, Veys P, Malech H, Cowan MJ. Chronic granulomatous disease: lessons from a rare disorder. Biol Blood Marrow Transplant 2011; 17: S123-S131, doi: 10.1016/j.bbmt.2010.09.008.